Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laurence Ridoux"'
Autor:
Ken Ogasawara, Christine Xu, Maria Palmisano, Laurence Ridoux, Vanaja Kanamaluru, Nicholas Siebers, Sekhar Surapaneni, Gopal Krishna
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:307-314
Fedratinib is an oral and selective kinase inhibitor with activity against wild type and mutationally activated Janus kinase 2 and FMS-like tyrosine kinase 3, for the treatment of adult patients with intermediate-2 or high-risk primary or secondary m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0641b20bacfb28483887a9a4d7dcad60
https://doi.org/10.1007/s00280-020-04121-0
https://doi.org/10.1007/s00280-020-04121-0
Autor:
Ken, Ogasawara, Christine, Xu, Vanaja, Kanamaluru, Nicholas, Siebers, Sekhar, Surapaneni, Laurence, Ridoux, Maria, Palmisano, Gopal, Krishna
Publikováno v:
Cancer chemotherapy and pharmacology. 86(2)
Fedratinib is an oral and selective kinase inhibitor with activity against wild type and mutationally activated Janus kinase 2 and FMS-like tyrosine kinase 3, for the treatment of adult patients with intermediate-2 or high-risk primary or secondary m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1b506ed5944979c2f21a8c7f8be8b086
https://pubmed.ncbi.nlm.nih.gov/32748109
https://pubmed.ncbi.nlm.nih.gov/32748109
Autor:
Dorothée Semiond, Ger-Jan Sanderink, Sally Clive, Laurence Ridoux, Lindsay Kelly, Carine Vincent, Corina Oprea, Christine Mauriac, Hélène Fontaine
Publikováno v:
Anti-cancer drugs. 26(3)
Cabazitaxel is a semisynthetic taxane approved for the treatment of patients with hormone-refractory metastatic prostate cancer (now known as metastatic castration-resistant prostate cancer) treated previously with a docetaxel-containing treatment re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a2eca23549fa9ba40bcc84e3e4b4dce
https://pubmed.ncbi.nlm.nih.gov/25462133
https://pubmed.ncbi.nlm.nih.gov/25462133
Autor:
Sally Clive, Christine Mauriac, Gerard Sanderink, Dorothée Semiond, Corina Oprea, Carine Vincent, Hélène Fontaine, Laurence Ridoux
Publikováno v:
Cancer Research. 72:749-749
Background Cabazitaxel (Cbz) is a novel semi-synthetic taxane that promotes the assembly of tubulin and stabilizes microtubules. In preclinical studies, Cbz demonstrated efficacy in both docetaxel-sensitive and -resistant tumor models (Bissery et al.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::662faccefc701aa82faad87b7ea12d7a
https://doi.org/10.1158/1538-7445.am2012-749
https://doi.org/10.1158/1538-7445.am2012-749